Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes

Dhatri Kodali, Hector Mesa, Ajay Rawal, Qing Cao, Pankaj Gupta

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Thrombocytosis at diagnosis is uncommon in myelodysplastic (MDS) and myelodysplastic/myeloproliferative (MDS/MPD) syndromes. We conducted a retrospective analysis to determine the clinical and haematopathological features of such patients, and the effect of thrombocytosis on prognosis. Of the 388 patients diagnosed with MDS from 1980-2006, 31 presented with thrombocytosis. The majority (71%) had low risk features and a low incidence of spontaneous bleeding or thrombo-embolic events. Compared to a case-matched control group of MDS and MDS/MPD patients without thrombocytosis of similar ages and IPSS scores, patients with thrombocytosis had a slightly lower probability of progression to a higher grade of MDS (P=0.03), equivalent risk of transformation to acute myeloid leukemia (AML), and a trend (P=0.07) towards longer overall survival (median 35.4 months compared to 27.6 months for controls).

Original languageEnglish (US)
Pages (from-to)2375-2380
Number of pages6
JournalLeukemia and Lymphoma
Issue number12
StatePublished - Dec 2007

Bibliographical note

Funding Information:
We thank Drs. Richard D. Brunning and Linda J. Burns (University of Minnesota, Minneapolis, Minnesota, USA) for helpful suggestions and critical review of the manuscript. This study was supported by the Veterans Health Administration.


  • Myelodysplastic syndrome
  • Myeloproliferative disease
  • Prognosis
  • Survival
  • Thrombocytosis


Dive into the research topics of 'Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes'. Together they form a unique fingerprint.

Cite this